Novartis collaborating with Lindy Biosciences for multi-target drug delivery

Novartis AG subsidiary Novartis Pharma announced a multi-target exclusive global licensing agreement and strategic collaboration with Lindy Biosciences, a biotechnology company specializing in innovative drug formulation and delivery technologies. The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Biosciences’ proprietary microglassification suspension technology. By delivering high concentrations of biologics, this technology increases the maximum dose that can be administered in a single subcutaneous injection. This has the potential to reduce healthcare costs while also improving patient comfort, convenience, and treatment compliance. Lindy Biosciences’ proprietary microglassification platform technology is poised to enable self-administration at home via pre-filled syringes or autoinjectors. The agreement’s financial terms include an upfront payment of $20M to Lindy Biosciences. Lindy Biosciences is also eligible to receive up to $934M in additional payments across multiple targets upon achieving certain regulatory, development and commercial milestones as well as tiered single-digit royalties on net sales.